Synthetic strategies and biological screening of novel pyrazolines as COX inhibitors

Betül Kaya; Begüm Nurpelin Sağlık; Yusuf Özkay; Zafer Asım Kaplancıklı

doi:10.55971/EJLS.1712793

Synthetic strategies and biological screening of novel pyrazolines as COX inhibitors

Abstract

In this study, a novel series of pyrazolines was afforded by the reaction of 2-hydrazinyl-N-(4-aminosulfonylphenyl)acetamide (2) and chalcone intermediates. The structures of target compounds were confirmed by IR, 1H NMR, 13C NMR and HRMS. The synthesized compounds were further evaluated for their in vitro COX inhibitory activity in order to discover new, effective and safer anti-inflammatory agents. Most of the compounds were more selective for COX-2 isozyme than COX-1. All compounds were weak inhibitors when compared to standard drugs ibuprofen, celecoxib and nimesulide. Among them, compounds 4a, 4e and 4f were the most potent inhibitors of COX-2. These findings suggest that these compounds could be lead compounds for further development as selective COX-2 inhibitors.

Keywords

Supporting Institution

This study was financially supported by Anadolu University Scientific Projects Fund, Project No: 1803S052

Project Number

1803S052

Ethical Statement

Ethics committee approval is not required as there are no in vivo or clinical studies.

Thanks

As the authors of this study, we thank Anadolu University Faculty of Pharmacy Central Research Laboratory (MERLAB), for their support and contributions.

References

Reddy KK, Vidya Rajan VK, Gupta A, Aparoy P, Reddanna P. Exploration of binding site pattern in arachidonic acid metabolizing enzymes, cyclooxygenases and lipoxygenases. BMC Res Notes. (2015);8:152. https://doi.org/10.1186/s13104-015-1101-4
Abdelgawad MA, Labib MB, Ali WAM, Kamel G, Azouz AA, EL-Nahass E. Design, synthesis, analgesic, anti-inflammatory activity of novel pyrazolones possessing aminosulfonyl pharmacophore as inhibitors of COX-2/5-LOX enzymes: histopathological and docking studies. Bioorg Chem. (2018);78:103–114. https://doi.org/10.1016/j.bioorg.2018.03.011
Elgohary MK, Abo-Ashour MF, Abd El Hadi SR, El Hassab MA, Abo-El Fetoh M E, Afify H, Abdel-Aziz HA, Abou-Seri SM. Novel anti-inflammatory agents featuring phenoxy acetic acid moiety as a pharmacophore for selective COX-2 inhibitors: Synthesis, biological evaluation, histopathological examination and molecular modeling investigation. Bioorg Chem. (2024);152:107727. https://doi.org/10.1016/j.bioorg.2024.107727
Ragab FAEF, Mohammed EI, Jaleel GAA, Abd El-Rahman AAM, Nissan YM. Synthesis of hydroxybenzofuranyl-pyrazolyl and hydroxyphenyl-pyrazolyl chalcones and their corresponding pyrazoline derivatives as COX inhibitors, anti-inflammatory and gastroprotective agents. Chem Pharm Bull. (2020);68(8):742-752. https://doi.org/10.1248/cpb.c20-00193
Abdellatif KR, Abdelall EK, Elshemy HA, Lamie PF, Elnahaas E, Amin DM. Design, synthesis of new anti-inflammatory agents with a pyrazole core: COX-1/COX-2 inhibition assays, anti-inflammatory, ulcerogenic, histopathological, molecular modeling, and ADME studies. J Mol Struct. (2021);1240:130554. https://doi.org/10.1016/j.molstruc.2021.130554
Perrone MG, Lofrumento DD, Vitale P, De Nuccio F, La Pesa V, Panella A, Calvello R, Cianciulli A, Panaro MA, Scilimati A. Selective cyclooxygenase-1 inhibition by P6 and gastrotoxicity: preliminary investigation. Pharmacology. (2015);95:22–28. https://doi.org/10.1159/000369826
Wallace JL. Mechanisms, prevention and clinical implications of nonsteroidal anti-inflammatory drug-enteropathy. World J Gastroenterol. (2013);19(12):1861–1876. https://doi.org/10.3748/wjg.v19.i12.1861
Tanaka A, Hase S, Miyazawa T, Ohno R, Takeuchi K. Role of cyclooxygenase (COX)-1 and COX-2 inhibition in nonsteroidal anti-inflammatory drug-induced intestinal damage in rats: relation to various pathogenic events. J Pharmacol Exp Ther. (2002);303(3):1248–1254. https://doi.org/10.1124/jpet.102.041715

Garcia-Rodriguez LA, Hern´ andez-Diaz S. Epidemiologic assessment of the safety of conventional nonsteroidal anti-inflammatory drugs, Am J Med. (2001);110:20-27. https://doi.org/10.1016/s0002-9343(00)00682-3
Ruan CH, So SP, Ruan KH. Inducible COX-2 dominates over COX-1 in prostacyclin biosynthesis: mechanisms of COX-2 inhibitor risk to heart disease, Life Sci. (2011);88:24–30. https://doi.org/10.1016/J.LFS.2010.10.017
Hwang SH, Wecksler AT, Wagner K, Hammock BD. Rationally designed multitarget agents against inflammation and pain. Curr Med Chem. (2013);20(13):1783–1799. https://doi.org/10.2174/0929867311320130013
Sun SX, Lee KY, Bertram CT, Goldstein JL. Withdrawal of COX-2 selective inhibitors rofecoxib and valdecoxib: impact on NSAID and gastroprotective drug prescribing and utilization. Curr Med Res Opin. (2007);23(8):1859-1866. https://doi.org/10.1185/030079907X210561
Ghifari TA, Wulan FF, Astuti E, Suryanti V, Putri DEK, Nur H, Wahyuningsih TD. Synthesis of furan-based pyrazoline as an anticancer agent: an in vitro and in silico approach toward COX-2 inhibition. J Mol Struct. (2025);1337:142125. https://doi.org/10.1016/j.molstruc.2025.142125
Ayman R, Abusaif MS, Radwan AM, Elmetwally AM, Ragab A. Development of novel pyrazole, imidazo [1, 2-b] pyrazole, and pyrazolo [1, 5-a] pyrimidine derivatives as a new class of COX-2 inhibitors with immunomodulatory potential. Eur J Med Chem. (2023);249:115138. https://doi.org/10.1016/j.ejmech.2023.115138
Labib MB, Fayez AM, EL-Shaymaa EN, Awadallah M, Halim PA. Novel tetrazole-based selective COX-2 inhibitors: Design, synthesis, anti-inflammatory activity, evaluation of PGE2, TNF-α, IL-6 and histopathological study. Bioorg Chem. (2020);104:104308. https://doi.org/10.1016/j.bioorg.2020.104308
Al-Turki DA, Al-Omar MA, Abou-Zeid LA, Shehata IA, Al-Awady MS. Design, synthesis, molecular modeling and biological evaluation of novel diaryl heterocyclic analogs as potential selective cyclooxygenase-2 (COX-2) inhibitors. Saudi Pharm J. (2017);25(1):59-69. https://doi.org/10.1016/j.jsps.2015.07.001
Harras MF, Sabour R, Alkamali OM. Discovery of new non-acidic lonazolac analogues with COX-2 selectivity as potent anti-inflammatory agents. Med Chem Commun. (2019);10:1775–1788. https://doi.org/10.1039/C9MD00228F
Nehra B, Rulhania S, Jaswal S, Kumar B, Singh G, Monga V. Recent advancements in the development of bioactive pyrazoline derivatives. Eur J Med Chem. (2020);205:112666. https://doi.org/10.1016/j.ejmech.2020.112666
Abdel-Sayed MA, Bayomi SM, El-Sherbeny MA, Abdel-Aziz NI, ElTahir KEH, Shehatou GSG, Abdel-Aziz AA-M. Synthesis, antiinflammatory, analgesic, COX-1/2 inhibition activities and molecular docking study of pyrazoline derivatives. Bioorg Med Chem. (2016);24:2032-2042 https://doi.org/10.1016/j.bmc.2016.03.032
Elgohary MK, Abd El Hadi SR, Abo-Ashour MF, Abo-El Fetoh ME, Afify H, Abdel-Aziz HA, Abou-Seri SM. Fragment merging approach for the design of thiazole/thiazolidine clubbed pyrazoline derivatives as anti-inflammatory agents: Synthesis, biopharmacological evaluation and molecular modeling studies. Bioorg Chem. (2023);139:106724. https://doi.org/10.1016/j.bioorg.2023.106724
Mantzanidou M, Pontiki E, Hadjipavlou-Litina D. Pyrazoles and pyrazolines as anti-inflammatory agents. Molecules. (2021);26(11):3439-3457. https://doi.org/10.3390/molecules26113439
Altintop MD, Temel HE, Özdemir A. Microwave-assisted synthesis of a series of 4, 5-dihydro-1H-pyrazoles endowed with selective COX-1 inhibitory potency. J Serb Chem Soc. (2023);88(4):355-365. https://doi.org/10.2298/JSC220907001A
Raut DG, Lawand AS, Kadu VD, Hublikar MG, Patil SB, Bhosale DG, Bhosale RB. Synthesis of asymmetric thiazolyl pyrazolines as a potential antioxidant and anti-inflammatory agents. Polycycl Aromat Compd. (2020);42(1):70–79. https://doi.org/10.1080/10406638.2020.1716028
Kharbanda C, Alam MS, Hamid H, Javed K, Bano S, Dhulap S, Ali Y, Nazreen S, Haider S. Synthesis and evaluation of pyrazolines bearing benzothiazole as anti-inflammatory agents. Bioorg Med Chem. (2014);22:5804–5812. https://doi.org/10.1016/j.bmc.2014.09.028
Yan R, Huang X, Deng X, Song M. Synthesis and activity evaluation of some pyrazole–pyrazoline derivatives as dual anti-inflammatory and antimicrobial Agents. Polycycl Aromat Compd. (2021);42(8):5006–5019. https://doi.org/10.1080/10406638.2021.1919156
Sihag M, Manuja A, Rani S, Soni R, Rani N, Malik S, Bhardwaj K, Kumar B, Kinger M, Miglani M, Aneja DK. Synthesis of pyrazole and pyrazoline derivatives of β-ionone: Exploring anti-inflammatory potential, cytotoxicity, and molecular docking insights. Eur J Med Chem Rep. (2024);12:100204. https://doi.org/10.1016/j.ejmcr.2024.100204
Thach TD, Nguyen TMT, Nguyen TAT, Dang CH, Luong TB, Dang VS, Banh KS, Luc VS, Nguyen TD. Synthesis and antimicrobial, antiproliferative and anti-inflammatory activities of novel 1, 3, 5-substituted pyrazoline sulphonamides. Arab J Chem. (2021);14(11):103408. https://doi.org/10.1016/j.arabjc.2021.103408
Kaya Çavuşoğlu B, Sağlık BN, Acar Cevik U, Osmaniye D, Levent S, Özkay Y, Kaplancıklı ZA. Design, synthesis, biological evaluation, and docking studies of some novel chalcones as selective COX‐2 inhibitors. Arch Pharm. (2021);354(3):2000273. https://doi.org/10.1002/ardp.202000273
Biovision COX‐1 Fluorescent Inhibitor Screening Kit (Catalog No: K548‐100) manual, http://www.biovision.com/manuals/K548.pdf
Biovision COX‐2 Fluorescent Inhibitor Screening Kit (Catalog No:K547‐100) manual, http://www.biovision.com/manuals/K547.pdf
Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. (2017);7:42717. https://doi.org/10.1038/srep42717

Details

Primary Language

English

Subjects

Pharmaceutical Biochemistry, Pharmaceutical Chemistry

Journal Section

Research Article

Authors

Betül Kaya ^*
0000-0002-1713-9485
Türkiye

Begüm Nurpelin Sağlık
0000-0002-0151-6266
Türkiye

Yusuf Özkay
0000-0001-5948-1855
Türkiye

Zafer Asım Kaplancıklı
0000-0003-2252-0923
Türkiye

Publication Date

August 31, 2025

Submission Date

June 3, 2025

Acceptance Date

July 14, 2025

Published in Issue

Year 2025 Volume: 4 Number: 2

DOI

https://doi.org/10.55971/EJLS.1712793

IZ

https://izlik.org/JA98SR74YY

Cite

RIS / Bibtex

APA

Kaya, B., Sağlık, B. N., Özkay, Y., & Kaplancıklı, Z. A. (2025). Synthetic strategies and biological screening of novel pyrazolines as COX inhibitors. European Journal of Life Sciences, 4(2), 64-76. https://doi.org/10.55971/EJLS.1712793

AMA

1.Kaya B, Sağlık BN, Özkay Y, Kaplancıklı ZA. Synthetic strategies and biological screening of novel pyrazolines as COX inhibitors. Eur J Life Sci. 2025;4(2):64-76. doi:10.55971/EJLS.1712793

Chicago

Kaya, Betül, Begüm Nurpelin Sağlık, Yusuf Özkay, and Zafer Asım Kaplancıklı. 2025. “Synthetic Strategies and Biological Screening of Novel Pyrazolines As COX Inhibitors”. European Journal of Life Sciences 4 (2): 64-76. https://doi.org/10.55971/EJLS.1712793.

EndNote

Kaya B, Sağlık BN, Özkay Y, Kaplancıklı ZA (August 1, 2025) Synthetic strategies and biological screening of novel pyrazolines as COX inhibitors. European Journal of Life Sciences 4 2 64–76.

IEEE

[1]B. Kaya, B. N. Sağlık, Y. Özkay, and Z. A. Kaplancıklı, “Synthetic strategies and biological screening of novel pyrazolines as COX inhibitors”, Eur J Life Sci, vol. 4, no. 2, pp. 64–76, Aug. 2025, doi: 10.55971/EJLS.1712793.

ISNAD

Kaya, Betül - Sağlık, Begüm Nurpelin - Özkay, Yusuf - Kaplancıklı, Zafer Asım. “Synthetic Strategies and Biological Screening of Novel Pyrazolines As COX Inhibitors”. European Journal of Life Sciences 4/2 (August 1, 2025): 64-76. https://doi.org/10.55971/EJLS.1712793.

JAMA

1.Kaya B, Sağlık BN, Özkay Y, Kaplancıklı ZA. Synthetic strategies and biological screening of novel pyrazolines as COX inhibitors. Eur J Life Sci. 2025;4:64–76.

MLA

Kaya, Betül, et al. “Synthetic Strategies and Biological Screening of Novel Pyrazolines As COX Inhibitors”. European Journal of Life Sciences, vol. 4, no. 2, Aug. 2025, pp. 64-76, doi:10.55971/EJLS.1712793.

Vancouver

1.Betül Kaya, Begüm Nurpelin Sağlık, Yusuf Özkay, Zafer Asım Kaplancıklı. Synthetic strategies and biological screening of novel pyrazolines as COX inhibitors. Eur J Life Sci. 2025 Aug. 1;4(2):64-76. doi:10.55971/EJLS.1712793